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y 6, 2013.his study sought to determine if the timing of hemoconcentration inﬂuences associated survival.Background Indicating a reduction in intravascular volume, hemoconcentration during the treatment of decompensated heart
failure has been associated with reduced mortality. However, it is unclear if this survival advantage stems from the
improved intravascular volume or if healthier patients are simply more responsive to diuretics. Rapid diuresis early
in the hospitalization should similarly identify diuretic responsiveness, but hemoconcentration this early would not
indicate euvolemia if extravascular ﬂuid has not yet equilibrated.Methods Consecutive admissions at a single center with a primary discharge diagnosis of heart failure were reviewed
(N ¼ 845). Hemoconcentration was deﬁned as an increase in both hemoglobin and hematocrit levels, then further
dichotomized into early or late hemoconcentration by using the midway point of the hospitalization.Results Hemoconcentration occurred in 422 (49.9%) patients (41.5% early and 58.5% late). Patients with late versus early
hemoconcentration had similar baseline characteristics, cumulative in-hospital loop diuretic administered, and
worsening of renal function. However, patients with late hemoconcentration versus early hemoconcentration had
higher average daily loop diuretic doses (p ¼ 0.001), greater weight loss (p < 0.001), later transition to oral diuretics
(p ¼ 0.03), and shorter length of stay (p < 0.001). Late hemoconcentration conferred a signiﬁcant survival
advantage (hazard ratio: 0.74 [95% conﬁdence interval: 0.59 to 0.93]; p ¼ 0.009), whereas early hemoconcentration
offered no signiﬁcant mortality beneﬁt (hazard ratio: 1.0 [95% conﬁdence interval: 0.80 to 1.3]; p ¼ 0.93) over no
hemoconcentration.Conclusions Only hemoconcentration occurring late in the hospitalization was associated with improved survival. These results
provide further support for the importance of achieving sustained decongestion during treatment of decompensated
heart failure. (J Am Coll Cardiol 2013;62:516–24) ª 2013 by the American College of Cardiology FoundationThe primary therapeutic objective in the majority of
patients hospitalized with acute decompensated heart
failure (ADHF) is optimization of volume status (1,2).
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Notably, the increase in concentration of red blood cells and
plasma proteins induced by intravascular volume contraction,
known as hemoconcentration, provides a surrogate for
changes in intravascular volume status during ﬂuid removal
(3–5). In the setting of ADHF treatment, hemoconcentration
seems to identify patients who have undergone aggressive
decongestion and has been associated with better post-
discharge survival (6–8). However, hemoconcentration
merely indicates that the plasma reﬁll rate has been exceeded
(i.e., ﬂuid has been removed from the intravascular space faster
than it could be replaced by extravascular ﬂuid). As a result,
hemoconcentration in isolation does not inform total body
volume status. Importantly, previous studies of hemo-
concentration focused on hemoconcentration at the time of
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517discharge, a time when overall volume status should have been
optimized. As such, the majority of patients with hemocon-
centration in these studies had objective evidence of
improvement in intravascular volume (hemoconcentration) in
addition to having the treating physician deem their overall
volume status sufﬁciently optimized to permit discharge.
Interpretation of these observations is challenging because it
is unclear to what degree this survival advantage stems from
a cause-and-effect association with aggressive decongestion or
simply from the fact that hemoconcentration may occur more
commonly in patients who are diuretic responsive and are
therefore healthier. However, if a patient underwent diuresis
early in an ADHF hospitalization with sufﬁcient rapidity to
exceed the plasma reﬁll rate, intravascular volume contraction
and hemoconcentration would occur. This outcome would be
true even if extravascular volume overload persisted at the time
of hemoconcentration. However, as diuresis was slowed
(perhaps prematurely in response to the improved signs of
intravascular volume status), extravascular ﬂuid would equil-
ibrate, leading to recurrence of intravascular volume overload
and loss or reduction in the degree of hemoconcentration.
Importantly, both early hemoconcentration (early HC) and
late hemoconcentration (late HC) should identify treatment-
responsive patients. However, the degree of volume optimi-
zation achieved over the hospitalization would likely be
superior in patients with the peak degree of hemoconcentra-
tion in proximity to discharge, when extravascular volume
status should be optimized to a greater degree. As a result,
comparing the survival of patients with peak hemoconcen-
tration early versus late in the hospitalization could provide
some insight into the relative importance of aggressive
decongestion versus treatment responsiveness in the improved
survival associated with hemoconcentration. As such, the
primary objective of the current study was to evaluate the
association between the timing of peak hemoconcentration
and subsequent survival.
Methods
Consecutive admissions from 2004 to 2009 to non-
interventional cardiology and internal medicine services at
the Hospital of the University of Pennsylvania with
a primary discharge diagnosis of congestive heart failure
were reviewed. Inclusion into this single-center study
required an admission B-type natriuretic peptide (BNP)
level of >100 pg/ml within 24 h of admission along with
serial hematocrit (Hct) and hemoglobin (Hgb) levels. To
focus primarily on the physiology and timing of deconges-
tion, patients with a length of stay <3 days (who likely
underwent limited decongestion) and patients with length
of stay >14 days (who likely had either atypical degrees of
congestion or nondiuresis-related problems driving the
length of stay) were excluded. Patients undergoing renal
replacement therapy were also excluded. In the event of
multiple hospitalizations for a single patient, only the ﬁrst
admission meeting the aforementioned inclusion criteriawas retained. Online Figure 1
provides additional details on
patient selection.
Hemoconcentrationwasdeﬁned
as an increase in bothHct andHgb
levels above admission values at any
time during the hospitalization.
Two positive markers of hemo-
concentration were required to
improve the signal-to-noise ratio
and to maintain some consistency
with our previous hemoconcentra-
tion deﬁnition (7). For the primary
analyses, the timing of hemo-
concentration was determined by
averaging the percentage of the
hospital stay that had elapsed at the
time of the peak Hct and Hgb
levels, then dichotomizing this
value into early HC and late HC by using the 50% point. The
relative timing of hemoconcentration was chosen to focus on
a patient’s overall improvement in intravascular volume status,
rather than the degree of euvolemia achieved after an arbitrary
period of time. This distinction is of practical importance for 2
reasons: 1) the amount of baseline extravascular volume overload
present in each patient is highly variable; and 2) extravascular and
intravascular volumes are in equilibrium.As a result, intravascular
euvolemia will on average take longer to achieve if severe extra-
vascular volume overload is present at baseline and therefore
confound the absolute time to peak hemoconcentration by the
degree of baseline volume overload. Secondary analysis focused
on the absolute time topeakhemoconcentrationwith adjustment
for length of stay.
Estimated glomerular ﬁltration rate (eGFR) was calcu-
lated by using the 4-variable Modiﬁcation of Diet in Renal
Disease equation (9). Worsening renal function (WRF) was
deﬁned as a 20% decrease in eGFR at any time during the
hospitalization (7,10–14). All-cause mortality was deter-
mined via the Social Security Death Index (15). Loop
diuretic doses were converted to furosemide equivalents with
1 mg of bumetanide ¼ 20 mg of torsemide ¼ 80 mg of
furosemide for oral diuretics, and 1 mg of bumetanide ¼ 20
mg of torsemide ¼ 40 mg of furosemide for intravenous
diuretics. Average daily loop diuretic doses were calculated
by dividing the total dose of loop diuretics over the hospi-
talization (in furosemide equivalents) by the hospital length
of stay. Given that hospital admissions over a 5-year period
were analyzed, a sensitivity analysis was undertaken to ensure
that the primary ﬁndings were consistent over this obser-
vation period and thus the cohort could be analyzed as
a whole. There was no signiﬁcant difference in the ﬁndings
between the ﬁrst quartile enrolled and the fourth quartile
enrolled (p interaction ¼ 0.52) or continuously across the
enrollment interval (p interaction ¼ 0.23). The study was
approved by the institutional review board of the Hospital of
the University of Pennsylvania.
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518Statistical analysis. The primary goal of the current anal-
ysis was to evaluate the association between timing of
hemoconcentration and post-discharge survival. As such, the
primary analysis focused on risk for all-cause mortality in
patients with early HC compared with late HC. Values
reported are mean  SD, median (quartile 1 to quartile 4),
and percentile. Independent Student t test or the Wilcoxon
rank sum test was used to compare continuous variables. The
chi-square test was used to evaluate associations between
categorical variables. Proportional hazards modeling was
use to evaluate time-to-event associations with all-cause
mortality. Candidate covariates entered in the model were
baseline characteristics with <10% missing values and
a univariate association with all-cause mortality at p  0.2.
Covariates that had a p value >0.2 but a theoretical basis for
potential confounding were forced into the model. Models
were built by using backward elimination (likelihood ratio
test) in which all covariates with a p value <0.2 were
retained (16). Adjusted survival curves were plotted for
patients with early HC, late HC, and no hemoconcentra-
tion; the x axis was terminated when the number at risk
was <10%.
Statistical analysis was performed by using SPSS version
20.0 (IBM SPSS Statistics, IBM Corporation, Armonk,
New York).
Results
Baseline characteristics of the 845 patients meeting inclu-
sion criteria are presented in Table 1. Overall, 422 (49.9%)
patients had an increase in both Hgb and Hct levels from
admission to their highest in-hospital level; 323 (38.2%)
had no increase; and 100 (11.8%) had an increase in only 1
of the 2 parameters. There was a greater incidence of an
increase in Hgb (58.5%) than Hct (53.3%) level. Among
patients whose Hct and Hgb levels increased above their
admission value, the mean increases in Hct and Hgb
were 10.2  9.0% and 9.3  9.5%, respectively. Patients
with increases in levels of both Hct and Hgb during
hospitalization had parameters consistent with aggressive
decongestion, including greater volume/weight loss, expo-
sure to loop diuretics, and deterioration in renal function
compared with those with no evidence of hemoconcentra-
tion (Online Table 1).
The mean time to peak Hct levels was 3.8  2.8 days and
to peak Hgb was 3.8  2.4 days. This equated to the mean
peak Hct and Hgb levels occurring 62.7  29.5% through
the hospitalization, with 41.5% of patients having peak
hemoconcentration in the ﬁrst 50% of the hospitalization
(early HC) and 58.5% with peak hemoconcentration after
the 50% mark (late HC). In patients with early HC, the
median time to peak in both Hgb and Hct was 2 days
(interquartile range [IQR]: 1 to 3 days) in the early HC
group and 4 days (IQR: 3 to 6 days) in the late HC group.
Overall, baseline characteristics were similar between patients
with early and late HC (Table 1). The cumulative amountof loop diuretic administered throughout the hospitalization
was not signiﬁcantly different between groups; however,
the average daily quantity of both intravenous and total
loop diuretic was signiﬁcantly greater in patients with late
HC compared with early HC (Table 2). In patients with
early HC, the maximum dose of intravenous diuretics was
administered earlier in the hospital course (25% [IQR: 12.5%
to 37.5%]) vs. 33% [IQR: 20% to 50%] of the way through
the hospitalization; p < 0.001), and the transition to oral
diuretics also occurred earlier in the hospital course (61%
[IQR: 39% to 80%]) vs. 67% [IQR: 50% to 83%] of the way
through the hospitalization; p ¼ 0.034). The odds of the
transition to oral diuretics falling in the ﬁrst half of the
hospitalization was signiﬁcantly higher for patients with early
HC (odds ratio [OR]: 2.2 [p ¼ 0.005]). The relative
frequency of hypokalemia (serum potassium <3.5 mEq/l;
p ¼ 0.99) and the daily amount of supplemental potassium
administered (p ¼ 0.89) was similar between early HC and
late HC. The change in eGFR from admission to the worst
in-hospital value (Table 2) and the overall incidence of WRF
was similar between late HC and early HC (OR: 1.1;
p ¼ 0.65). However, the greatest deterioration in renal
function occurred further through the hospital course (33%
[IQR: 0% to 67%] vs. 25% [IQR: 0% to 67%] of the way
through the hospitalization; p ¼ 0.003) and the odds of
WRF occurring in the latter 50% of the hospitalization was
greater in the late HC group (OR: 2.5; p ¼ 0.006). Notably,
the total and average daily ﬂuid/weight losses were signiﬁ-
cantly greater in patients with late HC (Figs. 1A and 1B), but
the length of stay was shorter (Table 2). Although the
increase from baseline to peak Hct and Hgb level was only
slightly greater among patients with late HC versus early
HC, the change in baseline to discharge Hct and Hgb level
was substantially greater in the late HC group (Fig. 2).
Notably, in patients with early HC, hemoconcentration was
largely transient such that only 34.5% with early HC
continued to meet criteria for hemoconcentration at the time
of discharge. In patients with early HC, the mean peak to
discharge hemodilution (change in Hct –9.6  8.0%; change
in Hgb –9.0  7.8%) did not differ from the initial degree of
hemoconcentration in these patients (p > 0.61 for both
comparisons).
Over a median follow-up of 3.4 years (IQR: 1.3 to 5.3
years), 439 (52%) patients died of any cause. The time from
hospital admission to ascertainment of all-cause mortality was
not signiﬁcantly different between patients with early HC,
late HC, or no hemoconcentration (p ¼ 0.2). Hemo-
concentration at any time during the hospitalization (i.e.,
either early HC or late HC) was not associated with
a signiﬁcantly better survival both before (hazard ratio [HR]:
0.85 [95% conﬁdence interval (CI): 0.70 to 1.0]; p ¼ 0.078)
and after (HR: 0.89 [95% CI: 0.72 to 1.1]; p ¼ 0.25)
adjustment for baseline characteristics (age, race, sex, hyper-
tension, systolic blood pressure, heart rate, edema, BNP,
serum sodium, eGFR, Hgb, Hct, loop diuretic dose, beta-
blocker use, and coronary artery disease). Interestingly, late
Table 1 Patient Characteristics
Characteristic Overall Cohort (n ¼ 845)
Hemoconcentration
p ValueEarly (n ¼ 175) Late (n ¼ 247)
Demographics
Age (yrs) 62.6  15.8 62.7  17.0 60.9  15.2 0.123
White race 34.1 41.7 33.6 0.089
Male 54.2 58.9 59.9 0.827
Medical history
Hypertension 73.8 68.4 77.1 0.045*
Diabetes 40.3 43.7 39.2 0.357
Atrial ﬁbrillation 28.3 32.2 25.5 0.134
Coronary artery disease 43.3 44.3 44.1 0.98
Ischemic etiology 25.1 25.7 29.6 0.386
Ejection fraction 40% 34.8 32.1 31.0 0.805
Admission physical examination
Heart rate (beats/min) 89.7  19.8 87.8  19.1 88.6  18.4 0.450
Systolic blood pressure (mm Hg) 138.2  34.4 134.1  34.5 135.7  31.7 0.907
Weight (kg) 90.5  29.8 86.6  29.2 93.1  28.5 0.033*
Jugular venous distention 35.2 37.8 38.8 0.847
Edema 42.0 39.0 43.4 0.36
Cardiac function
Ejection fraction (%) 27.5 (15–45) 26.3 (15–45) 25 (15–42.5) 0.771
Moderate or severe mitral regurgitation 43.2 43.4 43.0 0.934
Cardiac devices
Implantable cardioverter-deﬁbrillator 29.1 29.9 28.6 0.410
Biventricular pacemaker 19.4 19.7 19.1 0.892
Medications (admission)
Beta-blocker 68.0 68.0 70.4 0.591
ACE inhibitor or ARB 61.4 60.6 61.1 0.907
Digoxin 23.1 24.7 27.5 0.518
Aldosterone antagonist 15.6 17.2 17.0 0.949
Loop diuretic dose (mg) 40 (0–80) 40 (0–80) 40 (0–80) 0.907
Medications (discharge)
Beta-blocker 84.8 82.6 88.1 0.113
ACE inhibitor or ARB 78.3 80.7 79.8 0.828
Digoxin 22.1 23.3 23.5 0.962
Aldosterone antagonist 20.6 20.9 25.1 0.322
Loop diuretic dose (mg) 80 (20–160) 40 (20–120) 80 (40–160) 0.021*
Laboratory values
Serum sodium (mEq/l) 138.5  4.4 138.3  4.8 138.3  3.9 0.991
B-type natriuretic peptide (pg/ml) 1,299 (651–2,435) 1,252 (728–2,085) 1,372 (672–2,665) 0.316
eGFR (ml/min/1.73 m2) 60.3  28.9 60.6  28.9 64.0  29.8 0.232
BUN (mg/dl) 28.9  21.6 30.0  22.6 26.8  19.5 0.119
Hemoglobin (g/dl) 12.1  2.1 11.8  2.1 11.7  2.0 0.691
Hematocrit (%) 36.6  6.2 35.3  6.3 35.3  5.7 0.987
Values are mean  SD, %, or median (quartile 1–quartile 4). Jugular venous distension was determined by the admitting physician by checking “jugular venous
distension” on the admission history and physician template form. Edema was deﬁned as any edema greater than trace noted on the admission history and physical
form. *Signiﬁcant p value.
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; BUN ¼ blood urea nitrogen; eGFR ¼ estimated glomerular ﬁltration rate.
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519HC was associated with signiﬁcantly better survival compared
with both early HC (HR: 0.73 [95% CI: 0.56 to 0.96];
p ¼ 0.026) and no hemoconcentration (HR: 0.74 [95% CI:
0.59 to 0.93]; p ¼ 0.009). Mortality did not differ between
patients with early HC and no hemoconcentration (HR: 1.0
[95% CI: 0.80 to 1.3]; p ¼ 0.93). After adjusting for baseline
characteristics, late HC remained signiﬁcantly associated with
better survival compared with both early HC and no HC(Fig. 3). The survival advantage with late HC compared with
early HC remained signiﬁcant after controlling for the
absolute magnitude of admission to peak change in Hct and
Hgb levels and the length of stay (HR: 0.69 [95% CI: 0.52
to 0.92]; p ¼ 0.012). In addition, extensive adjustment
for baseline characteristics, in-hospital treatment-related pa-
rameters, and discharge medications (the aforementioned
baseline characteristics plus length of stay, admission to peak
Table 2 In-Hospital Treatment-Related Parameters
Parameter Overall Cohort (n ¼ 845)
Hemoconcentration
p ValueEarly (n ¼ 175) Late (n ¼ 247)
Diuretic administration
Total loop diuretic (mg) 400 (200–820) 410 (200–915) 440 (230–900) 0.637
Average total loop diuretic (mg/day) 80 (40–130) 66 (36–115) 90 (50–138) 0.001*
Total IV loop diuretic (mg) 240 (80–500) 200 (80–550) 280 (546–280) 0.221
Average IV loop diuretic (mg/day) 43 (17–85) 33 (10–69) 53 (20–70) 0.001*
Maximum 24-h dose of IV diuretic (mg) 80 (40–160) 80 (40–160) 100 (60–200) 0.081
Adjuvant thiazide diuretic 11.3 9.8 13.4 0.256
Total oral loop diuretic (mg) 120 (0–320) 160 (0–360) 120 (0–300) 0.323
In-hospital inotropes
Milrinone 13.1 14.5 10.0 0.166
Dobutamine 1.1 2.3 0.4 0.083
In-hospital maximum changes in laboratory parameters
Hematocrit (%) 5.4  8.4 10.1  10.7 10.7  7.8 0.012*
Hemoglobin (%) 5.4  8.6 9.8  11.2 10.6  8.7 0.014*
eGFR (%) 15.7  15.1 17.1  16.2 16.9  15.7 0.974
BUN (%) 39.5  51.0 45.1  58.8 47.8  55.9 0.315
Bicarbonate (%) 20.1  17.3 21.2  19.1 20.4  15.5 0.902
Admission to discharge change in laboratory parameters
Hematocrit (%) 2.1  11.0 0.3  11.8 7.2  8.8 <0.001*
Hemoglobin (%) 1.8  11.0 0.1  11.9 7.3  9.5 <0.001*
eGFR (%) 1.5  56.0 2.1  25.5 1.3  27.1 0.195
BUN (%) 20.9  50.7 22.2  55.7 31.6  54.0 0.017*
Bicarbonate (%) 10.6  18.9 10.9  18.2 10.6  18.0 0.53
Sodium (%) 0.7  3.8 0.45  3.2 1.0  5.3 0.688
Hospital course
Length of stay (days) 5 (4–8) 7 (4–10) 4 (3–5) <0.001*
Values are median (quartile 1–quartile 4), %, or mean  SD. *Signiﬁcant p value.
IV ¼ intravenous; other abbreviations as in Table 1.
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520change in Hct and Hgb, net ﬂuid output, total loop diuretic
administered, and inotrope use, as well as discharge beta-
blocker, angiotensin-converting enzyme/angiotensin receptor
blockers, spironolactone, digoxin, and loop diuretic dose)
minimally affected these results (HR: 0.65 [95% CI: 0.45 to
0.92]; p ¼ 0.016). Exploratory analysis comparing patients
with late HC who maintained hemoconcentration through
discharge (79.4% of late HC patients, n ¼ 196) versus early
HC patients who no longer met criteria for hemoconcentra-
tion at discharge (62.3% of early HC patients, n ¼ 109)
revealed a particularly pronounced survival advantage with
sustained late HC (adjusted for the aforementioned admis-
sion, in-hospital, and discharge parameters; HR: 0.43 [95%
CI: 0.25 to 0.72]; p ¼ 0.002).
Early HC versus late HC, deﬁned by using an absolute
rather than relative time to peak hemoconcentration, was not
associated with signiﬁcant differences in survival (p  0.16
for all cutoff points using days 1 through 14). However,
these ﬁndings were inﬂuenced by a signiﬁcantly longer
length of stay in the late HC groups. For example, deﬁning
late HC according to the median time to hemoconcentration
(3 days), the length of stay was signiﬁcantly greater with
late HC versus early HC (7 days [5 to 10] vs. 4 days [3 to 6];
p < 0.0001). After adjustment for length of stay, late HC(deﬁned by using the 3-day cutoff point [patient charac-
teristics are presented in Online Table 2]) was associated
with signiﬁcantly better survival than early HC (HR: 0.69
[95% CI: 0.51 to 0.95]; p ¼ 0.022), an association that
persisted after adjustment for admission, in-hospital, and
discharge parameters (HR: 0.59 [95% CI: 0.39 to 0.89];
p ¼ 0.011). Notably, late HC, which was deﬁned as a peak
in hemoconcentration occurring at very late time points,
such as after 7 days (adjusted HR: 0.48 [95% CI: 0.25 to
0.93]; p ¼ 0.028), 8 days (adjusted HR: 0.30 [95% CI: 0.13
to 0.71]; p ¼ 0.007), 9 days (adjusted HR: 0.24 [95% CI:
0.09 to 0.66]; p ¼ 0.006), and 10 days (adjusted HR: 0.26
[95% CI: 0.07 to 0.91]; p ¼ 0.035), was actually associated
with a progressively greater survival advantage compared
with early HC after controlling for length of stay.
Discussion
The principal ﬁnding of the current study was that
the timing of hemoconcentration during the treatment
of decompensated heart failure strongly inﬂuences the
associated mortality, with signiﬁcantly better survival for
patients with late HC compared with those with early HC
or no hemoconcentration. Interestingly, baseline disease
Figure 1 Weight and Fluid Losses
Total weight and net ﬂuid lost (A) during hospitalization and average daily weight
and ﬂuid losses (B) in patients with early versus late hemoconcentration (HC).
Figure 2
Degree of Admission to Peak HC and Admission
to Discharge HC in Patients With Early HC Versus
Late HC
HC calculated as the average percentage change in both hemoglobin and
hematocrit. Abbreviation as in Figure 1.
Figure 3
Adjusted Survival Curves of Patients With
Early, Late, and No HC
Comparison of late HC versus no HC, p ¼ 0.038; comparison of late HC versus
early HC, p ¼ 0.021; and comparison of early HC versus no HC, p ¼ 0.54.
Covariates adjusted for: age, race, sex, hypertension, systolic blood pressure,
heart rate, edema, B-type natriuretic peptide, serum sodium, estimated glomerular
ﬁltration rate, hemoglobin, hematocrit, loop diuretic dose, beta-blocker use, and
coronary artery disease.
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521severity indicators, total in-hospital loop diuretics admin-
istered, and the overall incidence of WRF were similar
between patients with early HC and late HC. However, the
pattern of diuretic approach seemed to differ with higher
average daily doses of loop diuretics, later transition to oral
diuretics, later time to peak deterioration in renal function,
and greater ﬂuid and weight loss with late HC versus early
HC. Notably, the majority of early HC patients experienced
substantial hemodilution subsequent to their early HC, such
that their discharge Hct and Hgb levels were similar to the
admission values. In conjunction with the lesser degree of
overall weight and volume loss, these observations suggest
that diuresis may have been de-escalated before complete
elimination of extravascular volume overload in early HC
patients. Overall, these ﬁndings indicate that the associa-
tion between hemoconcentration and better survival is
contingent not only on whether hemoconcentration can
be induced but also on the timing/durability of the
hemoconcentration.As a basic physiological principal, removal of intravascular
ﬂuid at a rate faster than it can be reﬁlled from extravascular
stores will lead to hemoconcentration. This physiology has
been used by nephrologists for decades to monitor intra-
vascular volume status during hemodialysis (3,4). Analo-
gously, some degree of hemodilution after cessation of ﬂuid
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522removal is also to be expected as extravascular ﬂuid comes to
equilibrium with intravascular volume. However, in the
setting of ADHF with severe extravascular volume overload,
recurrence of intravascular volume overload can be nearly
complete after abrupt cessation of early aggressive ﬂuid
removal. In a study by Guazzi et al. (17), severely volume-
overloaded patients were exposed to a brief period of high
rate of ultraﬁltration (500 cc/h), resulting in a 22% decrease
in plasma volume. Despite a stable weight maintained over
the next 48 h with oral diuretics, plasma volume completely
returned to pre-treatment values. Notably, both right- and
left-sided ﬁlling pressures were reduced with the interven-
tion, but unlike plasma volume, ﬁlling pressures did not
rebound and actually remained at the immediate post-
treatment levels. Similarly, in a study by Marenzi et al. (18),
24 h after removal of 7.5 liters of ﬂuid (ultraﬁltrate þ urine),
plasma volume was unchanged from pre-treatment levels,
but ﬁlling pressures were maintained at the improved im-
mediate post–ﬂuid removal levels. These observations
highlight the fact that via the substantial and dynamic
compliance of the capacitance vessels of the venous system,
ﬁlling pressures and blood volume may have little correla-
tion (19). Importantly, in the study by Marenzi et al. (18),
the mean right atrial pressure 24 h after ultraﬁltration was
reduced to w8 mm Hg. This ﬁnding indicates that
a signiﬁcant percentage of these patients likely had
a normalization of jugular venous pressure despite an
unchanged blood volume. As such, it is understandable how
transient or even a complete absence of hemoconcentration
can occur in the setting of substantial diuresis and how
hemoconcentration could be transient even in the setting of
continued slower diuresis. These ﬁndings reinforce the fact
that the vast majority of our surrogates for decongestion,
including right heart catheterization parameters and even
directly measured blood volume, only provide a snapshot of
the intravascular environment rather than a true measure of
global decongestion. The implication of this physiology is
that application of a one-size-ﬁts-all strategy of aggressive
diuresis to a prespeciﬁed/nonpatient speciﬁc time to hemo-
concentration is unlikely to be successful. Support for this
concept is provided by the ﬁnding that late HC deﬁned in
absolute terms (i.e., number of days to hemoconcentration)
was only associated with better survival after adjustment for
length of stay.
The association between hemoconcentration and im-
proved survival provides reassurance that the net clinical
beneﬁt from aggressive decongestion may outweigh the
adverse effects of decongestive therapies (6,7). However,
interpretation of this observational data is challenging
because it is unclear to what degree the improved survival
results directly from the aggressive decongestion or if
patients who respond to treatment with hemoconcentration
are healthier patients. Given that diuretic resistance is
a powerful prognostic indicator, it is intuitive that patients
responding to diuretics with an effective diuresis may have
lower disease severity (20–22). There are several ﬁndings inthe current analysis that argue that this is not the primary
factor driving these observations. First, both early and
late HC patients were likely diuretic responsive because
hemoconcentration occurred in both. Notably, the group
with early HC actually experienced hemoconcentration with
less aggressive treatment. Second, early HC patients had
similar maximum intravenous loop diuretic doses but earlier
administration of that maximum dose and an earlier tran-
sition to oral diuretics. This suggests that the inability to
maintain hemoconcentration was not purely a function of
a greater degree of diuretic refractoriness. Third, baseline
characteristics were remarkably similar, but essentially all in-
hospital treatment-related parameters trended toward
a more sustained/aggressive diuresis in the late HC group.
Fourth, mortality differences between groups persisted after
extensive adjustment for baseline, in-hospital, and discharge
parameters. These ﬁndings lend incremental support to the
concept that an association between hemoconcentration and
improved survival is not solely driven by treatment refrac-
toriness in the comparison group.
Although it seems probable that there was a difference in
the timing of de-escalation of therapy between the early HC
and late HC groups, which was probably not primarily
driven by diuretic refractoriness, the motivation for this de-
escalation is unknown. Although admission, discharge, and
available nondiuretic in-hospital characteristics were similar
between groups, differences in the ability to tolerate therapy
may have emerged during treatment. As a result, the
assumption that more aggressive/sustained diuresis in the
early HC group would have led to improved outcomes may
be incorrect. For example, factors such as hypotension,
WRF, adequacy of perfusion, or even a general ill-
appearance of the patient can (appropriately) factor into
the physician’s decision-making regarding subsequent
diuretic therapy. As such, early de-escalation of therapy
could have resulted from a physician’s erroneous conclusion
that the patient no longer required diuresis or the astute
recognition that the patient could no longer tolerate further
diuresis. As a result, it is possible that the differences in
survival were derived from differences in the ability of the
patients to tolerate sustained aggressive diuresis rather than
the sustained diuresis itself.
Study limitations. First, given the observational nature of
the current study, causality is impossible to demonstrate,
and residual confounding cannot be excluded. Furthermore,
the data were generated from a single center, and given that
local practice patterns can vary across institutions, it is
possible that these ﬁndings will not generalize to other
centers. Due to the modest size of our cohort, the ability to
rule out temporal variations in the association between early
HC and late HC with mortality is limited. Larger studies
will be needed to determine if changing practice patterns
over time inﬂuence these observations. In addition, exclu-
sion of patients who did not have a baseline BNP level
available further limits generalizability. Serial measures of
total protein and albumin were not available in this
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523population, markers which seem to have better operating
characteristics than Hct and Hgb levels (7). Notably, in
previous reports, Hct level alone was not signiﬁcantly
associated with WRF or mortality, and Hgb level alone did
not remain signiﬁcantly associated with mortality after
multivariate adjustment in a different study (6). Although
this limitation was likely overcome somewhat by increasing
the number of patients studied (n ¼ <340 in the previous
studies) and using both Hct and Hgb levels to deﬁne
hemoconcentration, it is unclear if the results would differ
signiﬁcantly if total protein and albumin data had been
available. Furthermore, the primary assumption is that
increases or decreases in the concentration of Hct, Hgb, and
plasma proteins are predominantly driven by changes in
volume status, but this hypothesis has never been tested.
Factors such as bleeding, phlebotomy, and the rate of
production of new red blood cells have an uncertain inﬂu-
ence, and we cannot exclude the possibility that these factors
do not similarly affect early HC and late HC; thus, the lack
of availability of these parameters is a signiﬁcant limitation
to the study. Although the analyses herein may provide
proof of concept when analyzed in large cohorts, on the
individual patient level, biological and assay variability will
likely preclude serial Hct and Hgb measures as a reliable
gauge of intravascular volume shifts. Although total and
peak doses of intravenous diuretics did not support the
hypothesis that the early HC group was highly diuretic
resistant, these are crude metrics to assess diuretic respon-
siveness, and it is possible that there were differences
between groups that may have inﬂuenced outcomes. In
addition, the lack of data on rehospitalizations is a signiﬁ-
cant limitation. Perhaps most importantly, the observational
nature of this study makes it impossible to exclude the
possibility that patients with early HC were not just “sicker,”
and the observed differences in survival actually had little to
do with the aggressiveness of diuresis. As a result of these
noted limitations, our ﬁndings should be considered
hypothesis-generating and serve primarily to motivate
further consideration of randomized trials of decongestive
strategies that can address causality.Conclusions
The association between hemoconcentration and survival is
strongly inﬂuenced by the timing at which peak hemo-
concentration occurs, with better survival in patients with late
HC compared with early HC or no hemoconcentration. It
cannot be determined from these data to what degree an
aggressive sustained diuretic strategy versus a durable
response to that strategy drove these observations. However,
these data do suggest that even when initial diuresis is rapid
enough to produce hemoconcentration, outcomes are inferior
if it is not maintained at a rate adequate to progressively
contract plasma volume throughout the hospitalization.
Given that volume management is the primary therapeuticobjective in most decompensated heart failure admis-
sions, and its completeness may have substantial inﬂuence
on subsequent outcomes, additional research is necessary
to develop more objective and reproducible therapeutic
endpoints.
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